Gain Therapeutics appoints Matthias Alder as CEO; Eric Richman resigns effective Sept 20, 2022

Gain Therapeutics, Inc.

Eric Richman resigned as CEO effective Sept 20, 2022; will remain on board through 2023 annual meeting and serve as senior advisor.
Matthias Alder, formerly COO, appointed President and CEO and to a Board seat; receives $500k base salary, 50% target bonus, option for 60,900 shares, and 10,200 RSUs.
Richman entitled to $27,200/month consulting fee for 12 months, plus 329,400 option and 54,900 RSUs vesting on first anniversary.
Board adopted new non-employee director compensation policy: annual cash retainers ($40k board, $7.5k audit, etc.) plus initial option of 21,000 shares and annual award of 10,500 shares.
One-time off-cycle annual option of 10,500 shares granted to each non-employee director on Sept 20, 2022, vesting before next annual meeting.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Eric Richman

Chief Executive Officer

GANX · Gain Therapeutics, Inc.

Effective: 2022-09-20
Successor: Matthias Alder
Filed: September 20, 2022, 7:59 PM ET

Eric Richman informed the Board of Directors (the “Board”) of his intent to resign as Chief Executive Officer, effective immediately.

Appointed

Matthias Alder

Director

GANX · Gain Therapeutics, Inc.

Effective: 2022-09-20
Filed: September 20, 2022, 7:59 PM ET

Matthias Alder, the Company’s former Chief Operating Officer, has been appointed by the Board to serve as the Company’s President and Chief Executive Officer and as a member of the Board, in each case effective September 20, 2022

Role change

Matthias Alder

President and Chief Executive Officer

GANX · Gain Therapeutics, Inc.

Effective: 2022-09-20
Filed: September 20, 2022, 7:59 PM ET

Matthias Alder, the Company’s former Chief Operating Officer, has been appointed by the Board to serve as the Company’s President and Chief Executive Officer and as a member of the Board, in each case effective September 20, 2022

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Eric Richman resigned as Chief Executive Officer at Gain Therapeutics, Inc..

Action: resigned
Role: Chief Executive Officer

Exact text from the filing

Eric Richman informed the Board of Directors (the “Board”) of his intent to resign as Chief Executive Officer, effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Matthias Alder was appointed as Director at Gain Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

Matthias Alder, the Company’s former Chief Operating Officer, has been appointed by the Board to serve as the Company’s President and Chief Executive Officer and as a member of the Board, in each case effective September 20, 2022

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Matthias Alder was appointed as President and Chief Executive Officer at Gain Therapeutics, Inc..

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

Matthias Alder, the Company’s former Chief Operating Officer, has been appointed by the Board to serve as the Company’s President and Chief Executive Officer and as a member of the Board, in each case effective September 20, 2022

View on SEC.gov

Gain Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-101644

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.